



**This new EP Publications report:**

- Provides an epidemiological forecast for key conditions associated with neuropathic pain in the US market in 2008, 2013, and 2018
- Forecasts the potential value of the neuropathic pain market for ten indications through 2018
- Presents expert analysis of the commercial potential and key differences among products in development for the treatment of neuropathic pain
- Describes the critical factors driving neuropathic pain market growth through 2018

**New for 2008 report:**

- Two New Indications:
  - Fibromyalgia
  - Neuropathic Cancer Pain
- Insights based upon WWMR's Pain Clinic Monitor, profiling neuropathic pain conditions

**Providing an  
Enhanced Perspective...**

On

**US Neuropathic  
Pain 2008  
4th Edition**

*Market Potential Through 2018*

**About WWMR, Inc.**

WWMR, Inc., is a leading marketing research and strategic consulting firm with global capabilities. Since 1994, WWMR, Inc., has provided high-quality, insightful proprietary studies to clients in the pharmaceutical, biotech, medical device, and diagnostics industries worldwide. Using primary and secondary research methodologies, WWMR, Inc., provides market opportunities and product assessments, competitive intelligence, forecasts, population projections, pre-launch product planning, post-launch product monitoring, product pricing strategy, database products, and on-site information center management. Enhanced Perspective Publications (EP Publications) is the multi-client service of WWMR, Inc.

## US NEUROPATHIC PAIN

### A Complex Market of Diverse Needs

Neuropathic pain (NP) can have chronic, debilitating impact on the lives of patients with a variety of conditions, including low back pain, diabetes, herpes, trigeminal neuralgia, HIV/AIDS, neuropathic cancer pain and fibromyalgia. Many patients and their physicians fail to realize the neuropathic nature of some patients' pain, including severe burning, stinging, and shooting pain. This general lack of awareness is largely due to the complicated nature of the onset of NP, difficulty in confirming diagnoses, and the lack of effective treatments.

### An Opportunity to Meet Unmet Need for Therapy

By 2018, there will be approximately 6 million individuals in US suffering from major NP conditions.

Given this substantial patient population, NP has received particular attention in recent years due to its relative resistance to conventional analgesic therapies. Importantly, many analgesic drugs, from non-steroidal anti-inflammatory drugs to strong opiates, have proven to be either ineffective or to provide only limited relief. More pharmacological therapies have been approved specifically for the treatment of NP in recent years.

There is still a great need to develop novel therapies that are safe and effective. Recent research elucidating the mechanisms of NP has provided new targets for pharmacological interventions that have captured the attention of the pharmaceutical industry.

### Report Objectives & Methodology

In this report WWMR, Inc., provides an overview for ten major conditions causing NP in the US market.

This report also summarizes WWMR, Inc.'s current understanding of NP mechanisms, and highlights promising targets for drug development. Also reviewed are new treatments already in development that offer the promise of improved pain management of NP in the near future.

Models representing patient populations and the commercial value (USD) of this market in 2008, 2013, and 2018 are presented. These models describe the important features of key conditions associated with NP:

- Neuropathic back pain
- Diabetic neuropathy
- Complex regional pain syndrome
- HIV/AIDS neuropathy

- Post-herpetic neuralgia
- Phantom limb pain
- Spinal cord injury
- Trigeminal neuralgia
- Fibromyalgia
- Neuropathic cancer pain

Expert analysis and commentary describing the future NP market are based on:

- WWMR's Pain Clinic Monitor, profiling neuropathic pain conditions
- Comprehensive analysis of uses for specific conditions, including estimations of prescription size, number of refills, and cost
- Evaluation of drugs in the NP drug pipeline, with conclusions on the future directions in treatment
- In-depth analysis of the medical literature, including treatment review articles, medical textbooks, epidemiology studies, and clinical studies
- Thorough review of country-specific and overall trends

Market and patient population forecasts are based on a consensus developed from industry experience, clinician input, and analysis of secondary sources.

WWMR's US Neuropathic Pain report will allow pharmaceutical and biotechnology executives to:

- Compare the epidemiology of neuropathic pain, including projected growth rates, by indication
- Recognize the specific conditions associated with neuropathic pain that have high market potential in the next 10 years
- Target specific patient populations who will benefit most from drugs in the neuropathic pain pipeline
- Anticipate upcoming competitors and product licensing opportunities
- Understand the type and level of unmet need in the US neuropathic pain market
- Recognize the impact of special market dynamics, including potential off-label usage, on product uptake forecasts

## About EP Publications

**Enhance your perspective through EP Publications, a service of WWMR, Inc. Each report pinpoints and evaluates key trends and markets, enabling clients to identify opportunities and augment strategic decisions. In-house consultants with industry experience use qualitative and quantitative research methodologies to provide the most comprehensive and insightful business intelligence available in the life sciences industry.**

**TABLE OF CONTENTS ■ US NEUROPATHIC PAIN**

**NEW IN 2008**

Two new indications:

- Fibromyalgia
- Neuropathic Cancer Pain

**I. EXECUTIVE SUMMARY**

**II. INTRODUCTION AND METHODOLOGY**

**III. PHYSIOLOGY OF PAIN**

A. Definition of Neuropathic Pain

1. Nerve injury
2. Long duration
3. Abnormal sensations
4. Aggravation by physiological processes
5. Cellular mechanisms of neuropathic pain

B. Definition of Neuropathic Pain States

1. Neuropathic low back pain
2. Diabetic neuropathy
3. Complex regional pain syndrome (CRPS)
4. Peripheral neuropathy in HIV/AIDS
5. Post-herpetic neuralgia
6. Phantom limb pain
7. Spinal cord injury
8. Trigeminal neuralgia (tic douloureux)
9. Cancer Pain
10. Fibromyalgia

**IV. CLINICAL ASSESSMENT OF NEUROPATHIC PAIN**

1. Qualitative description of pain
2. Standard quantitative pain measurement scales
3. Physical examination of the neuropathic pain patient

**V. EPIDEMIOLOGY - CURRENT AND FUTURE**

A. Neuropathic Low-Back Pain

1. Low-back pain
2. Low-back pain incidence and prevalence
3. Chronic low-back pain prevalence
4. Neuropathic, chronic low-back pain prevalence
5. Basis of target population
6. US neuropathic, chronic low-back pain population forecasts

B. Diabetic Neuropathy

1. Diabetic neuropathy
2. Diabetes prevalence
3. Diabetic neuropathy prevalence
4. Painful diabetic neuropathy prevalence
5. Moderate-to-severe diabetic neuropathic pain prevalence
6. Chronic moderate-to-severe diabetic neuropathic pain prevalence
7. Basis of target population forecasts
8. US diabetic neuropathy population forecasts

C. Complex Regional Pain Syndrome

1. Complex regional pain syndrome
2. Complex regional pain syndrome prevalence
3. Complex regional pain syndrome severity
4. Basis of target population estimation
5. US CRPS population forecasts

D. HIV/AIDS Neuropathic Pain

1. HIV/AIDS pain
2. AIDS incidence and prevalence
3. HIV (not AIDS) prevalence
4. HIV/AIDS pain prevalence
5. HIV/AIDS neuropathic pain prevalence
6. Basis of target population forecasts
7. US HIV/AIDS neuropathy population forecasts

E. Post-Herpetic Neuralgia

1. Post-herpetic neuralgia
2. Herpes zoster incidence
3. Post-herpetic neuralgia incidence
4. Incidence of persistent post-herpetic neuralgia
5. Persistent post-herpetic neuralgia prevalence
6. Basis of target population forecasts
7. US post-herpetic neuralgia population forecasts

F. Phantom Limb Pain

1. Phantom limb pain
2. Amputation incidence and prevalence
3. Phantom limb pain incidence and prevalence
4. Basis of target population estimation
5. US phantom limb pain population forecasts

G. Spinal Cord Injury

1. Spinal cord injury
2. Spinal cord injury incidence
3. Spinal cord injury prevalence
4. Spinal cord injury chronic pain prevalence
5. Basis of target population estimation
6. US spinal cord injury population forecasts

H. Trigeminal Neuralgia

1. Trigeminal neuralgia
2. Trigeminal neuralgia incidence and prevalence
3. Basis for target population
4. US trigeminal neuralgia population forecasts

I. Neuropathic Cancer Pain

1. Cancer pain
2. Incidence of cancer
3. Incidence of neuropathic cancer pain
4. Prevalence of neuropathic cancer pain
5. Basis for target population
6. US Neuropathic cancer pain population forecasts

J. Fibromyalgia

1. Fibromyalgia
2. Incidence of fibromyalgia
3. Prevalence of fibromyalgia
4. Diagnosed and treated population
5. Basis for target population
6. US fibromyalgia population forecasts

**VI. APPROACHES TO TREATMENT OF NEUROPATHIC PAIN**

A. Actual Clinical Practice

1. Antidepressants
2. Anticonvulsants
3. Local anesthetics, regional nerve blocks, and sympathetic nerve blocks
4. Antiarrhythmics
5. Non-narcotic synthetic opioids
6. Opioids and semi-synthetic narcotics
7. Muscle relaxants
8. NMDA receptor antagonists
9. Steroids
10. VR-1 receptor agonists
11. Non-steroidal anti-inflammatory agents (NSAIDs)
12. Non-pharmacologic treatments

B. Clinical Practice Guidelines

C. Limitations of Current Treatment

D. Promising New Approaches

E. Future Trends

F. Drugs in Clinical Development to Treat Neuropathic Pain

1. Recent launches/approvals
2. Current pipeline
  - 2.1 Phase III, Preregistration, and Registration
  - 2.2 Phase II
  - 2.3 Phase I
  - 2.4 Discontinued or suspended drugs
  - 2.5 Marketed agents with significant off-label usage for NP

**VII. MARKET FORECASTS AND ESTIMATES, CURRENT AND FUTURE**

A. Current Sales of Pharmaceutical Products, By Drug Class and Condition

1. 2008 US market: summary by drug class

- 1.1 Anticonvulsants
- 1.2 Oral opioids
- 1.3 Antidepressants
- 1.4 Other drug classes

2. 2008 US market: summary by neuropathic pain condition

- 2.1 Fibromyalgia
- 2.2 Neuropathic back pain
- 2.3 Diabetic neuropathy (DN)
- 2.4 Neuropathic cancer pain
- 2.5 Post-herpetic neuralgia (PHN)
- 2.6 Complex regional pain syndrome (CRPS)
- 2.7 Trigeminal neuralgia (TN)
- 2.8 Phantom limb pain
- 2.9 HIV/AIDS neuropathic pain
- 2.10 Spinal cord injury

Methodology

B. Market Forecast for Neuropathic Pain



**To Order US NEUROPATHIC PAIN or request more information on current/future publications**

- I would like to purchase \_\_\_\_\_ **hardcopy(s) of 2008 US NEUROPATHIC PAIN** ..... \$ **7,500**
- \$500 for each additional copy  PDF or  Printed Copy..... \$ \_\_\_\_\_
- \$1,850 for a worldwide license ..... \$ \_\_\_\_\_
- California residents add 8.25% sales tax ..... \$ \_\_\_\_\_
- Pennsylvania residents add 6% sales tax..... \$ \_\_\_\_\_
- I am enclosing total payment ..... \$ \_\_\_\_\_

Note: Purchasers outside the United States must provide prepayment in US funds. Remit by credit card, bank transfer, or check (payable to WWMR, Inc.)

- My Federal Express number is: \_\_\_\_\_
- Domestic Shipping & Handling (2 day service) - Add \$35.00 ..... \$ \_\_\_\_\_
- International Shipping & Handling (4-5 day service) - Add \$120.00..... \$ \_\_\_\_\_
- Bill my company. PO#: \_\_\_\_\_
- MasterCard                       Visa                                       American Express

Account Number: \_\_\_\_\_ Exp. Date: \_\_\_\_\_

NAME ON CREDIT CARD \_\_\_\_\_

SIGNATURE \_\_\_\_\_

Information in EP Publications is for the confidential use of purchasing companies. Purchaser agrees not to circulate any EP Publications outside his/her organization.

Make checks payable to: **WWMR, Inc.**

Mail to: WWMR, Inc. 2929 Campus Drive, Suite 200, San Mateo, CA 94403

**Fax ORDER/REQUEST to: 650-312-1570 or call toll free 888-947-2339 x 112**

Email to: Michelle\_Nordstrom@wwmr.com

NAME \_\_\_\_\_

TITLE \_\_\_\_\_

COMPANY \_\_\_\_\_

ADDRESS \_\_\_\_\_ MAIL STOP \_\_\_\_\_

CITY \_\_\_\_\_ STATE \_\_\_\_\_ ZIP \_\_\_\_\_

PHONE \_\_\_\_\_ FAX \_\_\_\_\_

SIGNATURE \_\_\_\_\_ DATE \_\_\_\_\_

Please send me information on current/future publications covering the following topics:

- Pain Clinic Monitor –US (Profiling 27 Pain Conditions)**
- 2008 Cancer Pain**
- 2009 Back Pain**
- Please send information on WWMR’s Marketing Research and Consulting Services**